Scroll Up
Scroll Down
Play Play Play Play
Unregistered User
Click here if this is not your Personal Edition
 
Contact Us | Free E-Mail Updates | Journals | Register a colleague
 
 
Psoriasis
 
   
 
SEARCH   
Doctor's Guide Free CME
Medline
Congress Resource Centre
 

 EXPLORE :
   Most Read News
 All News  All News
 All Webcasts / CME  All Webcasts / CME
 All Cases  All Cases
 Congress Resource Centre  Congress Resource Centre
 All Medical Resources  All Medical Resources
 Medical  My Personal Edition



Warning | Privacy

 

 
 Recent news - Psoriasis
    Psoriasis Associated With Cardiovascular Disease, Increased Mortality - (DGNews)
    Chondroitin Sulphate Effective in Patients With Concomitant Knee Osteoarthritis and Psoriasis: Presented at EULAR - (DGDispatch)
    Golimubab Shows Long-Term Efficacy in Treatment of Psoriatic Arthritis: Presented at EULAR - (DGDispatch)
    Nationwide Recall of Remaining Batches of Efalizumab Initiated in Europe - (DGDispatch)
    Home versus outpatient ultraviolet B phototherapy for mild to severe psoriasis: pragmatic multicentre randomised controlled non-inferiority trial (PLUTO study) - (BMJ)

    News archive

     Recent webcasts/CME - Psoriasis
    • Using Biologics to Improve Both Physical and Social Function in Rheumatic Diseases
    • Rheumatic Diseases: Using Anti-TNF-alpha Agents to Improve Everyday Patient Function
    • Treating to Target: Long-Term Safety and Efficacy in Rheumatoid Arthritis
    • Moderate-to-Severe Psoriasis and Psoriatic Arthritis: Reducing the Clinical and Economic Burden Through Effective Treatment Protocols
      Treatment Options for Moderate to Severe Plaque Psoriasis

      Webcasts/CME archive

       Recent cases - Psoriasis
        Concomitant Xeroderma Pigmentosum and Disseminated Small Plaque Psoriasis - The First Case of an Antinomic Association: A Case Report
        Extensive Psoriasis Induced by Pegylated Interferon: A Case Report
        Pulmonary Sarcoidosis Associated with Psoriasis Vulgaris: Coincidental Occurrence or Causal Association? Case Report
        Leukemia Cutis Resembling a Flare-Up of Psoriasis
        Pimecrolimus 1 Percent Cream in the Treatment of Psoriasis in a Child

        Cases archive
          




        my personal edition > psoriasis > news
        divider

          E-Mail this DGDispatch to a colleague

        DGDispatch


        Efalizumab Safe for Treatment of Chronic Plaque Psoriasis: Presented at EADV

        By Jill Stein

        RHODES, GREECE -- October 5, 2006 -- The recombinant, humanised, monoclonal antibody efalizumab does not increase the risk of arthropathy adverse events in patients with chronic plaque psoriasis, investigators reported here at the 15th Congress of the European Academy of Dermatology and Venereology (EADV).

        Carlo Pincelli, MD, associate professor, dermatology division, University of Modena, Modena, Italy, and colleagues conducted a pooled safety analysis of data in more than 3,000 patients with moderate-to-severe chronic plaque psoriasis enrolled in 7 phase 2/3/4 clinical trials.

        "Chronic plaque psoriasis is an immune-mediated disease that frequently requires long-term therapy to manage symptoms effectively," Dr. Pincelli observed in his presentation on October 4th. "However, traditional systemic therapies such as methotrexate and cyclosporine have treatment-limiting side effects that may prevent continuous use over the long term."

        New targeted biologic therapies such as efalizumab show a better risk-benefit profile for patients with chronic plaque psoriasis, he said.

        "Psoriatic arthritis constitutes a major consideration in patients who are receiving long-term treatment for their psoriasis, and the prevalence of arthritis in such patients has been reported to be as high as 30%," he continued. "Despite the observation that symptoms of arthropathy adverse events can be managed successfully with nonsteroidal anti-inflammatory drugs, it is very important to assess the potential role of efalizumab with respect to the incidence of arthropathy adverse events."

        Arthropathy adverse events were defined either by Coding Symbols for Thesaurus of Adverse Reaction Terms (CO-START)-preferred terms -- 'arthritis' and 'arthrosis' -- or the Medical Dictionary for Regulatory Activities (MedDRA) terminology-preferred terms -- 'arthritis not otherwise specified (NOS),' 'psoriatic arthropathy,' 'arthropathy NOS,' 'monoarthritis,' 'polyarthritis,' and 'osteoarthritis NOS.'

        Each period of efalizumab exposure was analysed. The first treatment period referred to the period during which patients received 12 weeks of weekly subcutaneous efalizumab dose of 1 mg/kg or placebo in a randomised, blinded manner. The extended treatment or retreatment periods were open-label periods where patients received 1 or 2 mg/kg of subcutaneous efalizumab for an additional 12 weeks of therapy. The long-term periods included 12- week treatment segments from 2 open-label, long-term studies for up to 3 years.

        The incidence of arthropathy adverse events per patient/year was similar for placebo- and efalizumab-treated patients during the first treatment period (0.16 and 0.15, respectively).

        During the extended treatment and retreatment periods, an incidence of 0.17 and 0.12 patient/year was seen, respectively.

        Three-month segment analysis from long-term periods showed a similar and stable incidence of arthropathy adverse events during lengthy treatment exposure (range 0.06-0.19 patient/year).

        Dr. Pincelli said the study is 1 of the largest safety analyses conducted with patients treated for chronic plaque psoriasis.

        The trial was sponsored by Serono.


        [Presentation title: Efalizumab Therapy and Incidence of Arthropathy Adverse Events: A Pooled Safety Analysis From 7 Clinical Trials. Abstract PO35.115]



        E-Mail this DGDispatch to a colleague   To print, use this version






        All contents Copyright (c) 1995-2009 Doctor's Guide Publishing Limited. All rights reserved.



        The NTK initiative. Physicians helping physicians identify Need-To-Know science
           Feedback
        Please rate this article: Strongly DISAGREE...Strongly AGREE NTK logo
        Question 1 - Physicians need to become aware of this information as soon as possible. Question 2 - This information is likely to have an impact on the way physicians practice medicine.
        1
        2
        3
        4
        5
        6
        7
        Send